- Discontinuing Denosumab: Can It Be Done Safely? A Review of the Literature
-
Tay WL, Tay D
- KMID: 2529210
- Endocrinol Metab.
- 2022 Apr;37(2):183-194.
- doi: 10.3803/EnM.2021.1369
Denosumab, which has been approved for the treatment of osteoporosis since 2010, is a fully humanised monoclonal antibody against a cytokine, receptor activator of nuclear factor kappa B ligand (RANKL),... -
- CITED
-
- Close
- SHARE
-
- Close
- Comparison of the Osteoporosis Self-Assessment Tool for Asians and the fracture risk assessment tool - FRAX to identify densitometric defined osteoporosis: A discriminatory value analysis in a multi-ethnic female population in Southeast Asia
-
Chandran M, Chin YA, Choo KS, Ang WC, Huang XF, Liu XM, Tay D, Aung TKK, Ali A, Thu WPP, Logan S, Yan SX, Lekamwasam S, Hao Y
- KMID: 2503943
- Osteoporos Sarcopenia.
- 2020 Jun;6(2):53-58.
- doi: 10.1016/j.afos.2020.04.001
Objectives: The accuracy of FRAX® as a screening tool to identify osteoporosis and how it compares with tools such as Osteoporosis Self-Assessment Tool for Asians (OSTA), in Southeast Asian women... -
- CITED
-
- Close
- SHARE
-
- Close
